# A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes

Study · id `cardio:ct-nct06972732` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06972732](<https://clinicaltrials.gov/study/NCT06972732>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06972732

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 204 participants.

## Technical summary

Registry record NCT06972732. Randomized; no masking; primary purpose treatment. Start 2025-06-11 (actual); primary completion 2026-10-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 204 participants (planned count; ClinicalTrials.gov record NCT06972732, source copy `cardio:ctgov-nct06972732-2025-09-15`, retrieved 2026-10-26)
- Started: 2025-06-11 (actual) (ClinicalTrials.gov record NCT06972732, source copy `cardio:ctgov-nct06972732-2025-09-15`, retrieved 2026-10-26)
- Primary completion: 2026-10-01 (anticipated) (ClinicalTrials.gov record NCT06972732, source copy `cardio:ctgov-nct06972732-2025-09-15`, retrieved 2026-10-26)
- Completion: 2026-10-01 (anticipated) (ClinicalTrials.gov record NCT06972732, source copy `cardio:ctgov-nct06972732-2025-09-15`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT06972732, source copy `cardio:ctgov-nct06972732-2025-09-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06972732-2025-09-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes
- Acronym: TELOS
- Condition: Type 2 Diabetes
- Intervention (Drug): Metformin
- Intervention (Drug): Dapagliflozin/Pioglitazone
- Intervention (Drug): Dapagliflozin/Sitagliptin
- Lead sponsor: Boryung Pharmaceutical Co., Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Boryung Pharmaceutical Co., Ltd (`cardio:org-boryung-pharmaceutical-co-ltd`)

## Provenance

Content hash: 39df9c773cc1af3fe1d27b38c3cd1457db781d25c1a71ceaff092ca40b06a8ca
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
